Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CryJ2-DNA-LAMP Vaccine ID Administration for Japanese Red Cedar Allergy
NCT02146781Phase 1Completed
- Sponsor
- Immunomic Therapeutics, Inc.
- Start
- Jun 2014
- Primary completion
- Mar 2015
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, single-blind trial of ASP4070 in Japanese cedar pollinosis (3 arms), sponsored by Immunomic Therapeutics, Inc. Primary endpoint: Number of participants with Adverse Events at 132 days. Started Jun 2014; status: completed.
02
Drugs
ASP4070
03
Conditions
Japanese cedar pollinosis
Beyond the preview
Go deeper on NCT02146781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146781.